New Therapy Protocol for Pancreatic Cancer Developed in Spain

Researchers in Spain have introduced a treatment protocol that may significantly change the landscape of pancreatic cancer treatment.

This type of cancer is notably aggressive and challenging to address, often diagnosed late due to vague symptoms like back pain and fatigue that many people tend to overlook.

Unfortunately, by the time most patients receive a diagnosis, over 60% already have stage 4 pancreatic cancer.

Additionally, the cancer’s biology makes it resistant to regular treatments like chemotherapy.

Currently, treatments focus on blocking KRS, a genetic mutation found in about 90% of pancreatic cancer cases. However, the effectiveness is limited since tumors typically develop resistance within a few months.

But, the team at the National Cancer Research Center (CNIO) in Spain claims to have discovered a combination of three drugs that can prevent this resistance.

Their recent study published in a scientific journal shows that this treatment can completely eliminate pancreatic tumors in mice, with minimal side effects.

This innovative strategy employs a mix of KRAS inhibitors, proteolytic agents, and lung cancer drugs, allowing for a more comprehensive attack on the KRAS mutations.

Applying this three-pronged approach has reportedly led to the permanent elimination of pancreatic tumors in the studied mice.

The authors of the study express optimism, suggesting their findings “pave the way for the design of combination therapies that may improve survival.” It’s encouraging, especially in light of the bleak outlook associated with pancreatic cancer.

According to estimates, about 67,530 individuals will be diagnosed with pancreatic cancer in the U.S. this year, leading to around 52,740 fatalities.

Despite the promising evidence, the research team acknowledges that translating this success into clinical applications will be complex and likely won’t happen immediately.

Mariano Barbacid, who leads the CNIO Experimental Oncology Group, stated, “While the experimental results achieved are unprecedented, we are still not ready to begin clinical trials for the triple therapy.”

Yet, despite the challenges ahead, Barbacid and his team remain hopeful about their potential to reshape pancreatic cancer treatment and its prognosis.

“These results might lead to new therapeutic avenues for enhancing clinical outcomes in the near future,” he remarked.

This represents another advance in the ongoing battle against pancreatic cancer. Last year, for instance, researchers at UCLA created a cell-based immunotherapy capable of targeting and annihilating pancreatic cancer cells, even after they migrate to other organs.

Early studies indicated that this treatment slowed tumor growth and extended survival, enduring even in the tough conditions posed by solid tumors.

Moreover, British scientists are also exploring breathalyzers that could detect cancer, which experts believe could represent a monumental leap forward in tackling this deadly illness.